Full-Time
Analyst – Investor Relations and External Communications
Updated on 9/3/2026
Precision AQ
501-1,000 employees
Data-driven drug access and launches
Compensation Overview
$70k - $93k/yr
New York, NY, USA
Hybrid
Hybrid work environment; occasional travel is required.
Bachelor's
 Growth & Marketing (1) |
|---|
Get referred to Precision AQ
See people who can refer or advise you
- 1–2 years of prior applicable experience, including work or internship experience, in a service industry requiring direct customer contact; healthcare and/or finance experience is preferred.
- A bachelor's degree is required.
- High standards of quality control and client service, with meticulous attention to detail.
- Ability to successfully manage multiple projects from conception to completion in a fast-paced team environment.
- Strong written and spoken communication skills, with particular attention to language and nuance, and the ability to follow and shape evolving company stories.
- Critical-thinking ability, initiative, and the ability to conceptualize and synthesize sophisticated research analyses and generate ideas.
- Proactive problem-solving ability with an analytical skill set, including conducting research and analysis and applying learned strategies and tools.
- Project-management skills, including organizing and managing complex logistics and datasets and planning and executing roadshows, meetings, and other investor events.
- Ability to work independently and collaboratively in a team-based, hybrid environment.
- Proficiency with the Microsoft suite, including PowerPoint and Excel.
- Competence in technology-driven environments, including artificial intelligence and various tools and platforms.
- Commitment to the success and growth of IREC and the entire team.
- Provide proactive daily logistical and strategic investor relations and public relations support to client accounts, executing at the direction of the client and account lead and meeting deadlines.
- Develop initial drafts of collateral materials, including press releases, corporate PowerPoint presentations, earnings scripts, messaging documents, media pitches, talking points, and strategic plans.
- Conduct research projects and targeting analyses and synthesize data and research into key takeaways.
- Conduct roadshows, meetings, and other investor events, including outreach campaigns.
- Plan events and provide on-site support, including occasional travel.
- Monitor client updates, industry trends, regulatory developments, competitive dynamics, and relevant investors, media, and reporters, and share findings with the IREC team and clients.
- Conduct ongoing and ad hoc media monitoring and develop related reporting documents.
- Support joint investor-relations and public-relations accounts.
- Manage up and across account teams while maintaining professional conduct and communication.
- Champion diversity, equity, and inclusion.
- Support the development of new-business materials.
- Cultivate relationships with investors, analysts, bankers, and journalists to enhance visibility and credibility.
- Represent the agency at industry events, conferences, and investor forums.
- Contribute to operational, growth, and strategy initiatives for Precision AQ.
- Generate ideas and identify opportunities for the firm and its clients.
- Experience in healthcare and/or finance.
Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
N/A
Get referred to Precision AQ
See people who can refer or advise you
Simplify's Take
What believers are saying
- February 17, 2026 hires Yahya Anvar and Emma Hawe deepen AI and HTA capabilities.
- August 12, 2026 Candice Subero hire boosts marketing-led customer engagement and commercial growth.
- Precision AQ’s 2025 Phluence investment advances agentic patient solutions, reducing post-Rx service costs.
What critics are saying
- Precision AQ reported $314.5 million revenue in 2024, down 7%, signaling slower growth.
- Phluence integration in November 2025 risks distracting teams while AI patient-service economics remain unproven.
- If pharma shifts to in-house AI access tools, Precision AQ’s HUB model weakens.
What makes Precision AQ unique
- Precision AQ works with all top 30 pharma companies and 350+ active engagements in 2026.
- Its 2024 rebrand unified pricing, HEOR, medical affairs, and omnichannel capabilities under one platform.
- Precision AQ has launched over 450 drugs, creating embedded launch expertise across therapeutics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Parental Leave
Performance Bonus
Company News
Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.
Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.
-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S
HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...